Avalon, GSK fund two more startups under collaboration
This article was originally published in Scrip
Executive Summary
Avalon Ventures and GlaxoSmithKline have launched Silarus Therapeutics and Thyritope Biosciences, the second and third San Diego-based biotechnology companies formed under a partnership that Avalon and GSK initiated in 2013 to fund up to 10 new startup firms.
You may also be interested in...
GSK Buys One Of Eight Firms Formed In VC Partnership With Avalon
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
Arena Updates Etrasimod Timelines, Introduces New Drug Candidate
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.
Need a specific report? 1000+ reports available
Buy Reports